Oral Hep C Trio Cured Over 90 Percent in Phase II Trial
Share
Follow Us
Abbott Hepatitis C Combo Impressive in Small Study
From U.S. Centers for Disease Control and Prevention
April 6, 2012
A combination of oral hepatitis C drugs being developed by Abbott Laboratories realized cure rates exceeding 90 percent in treatment-naïve patients, according to a small, mid-stage study. The results, released Wednesday, will be presented later this month in Barcelona at a meeting of the European Association for the Study of the Liver.
For 12 weeks, patients in the Phase II trial, known as “Co-Pilot,” received Abbott’s protease inhibitor ABT-450, boosted by the antiviral drug ritonavir with its polymerase inhibitor ABT-333, and ribavirin, which is used in all current hepatitis C regimens. Patients’ blood virus levels were checked 24 weeks later for a sustained virologic response. Those achieving SVR were considered cured.
Continue reading this entire article:
http://www.thebody.com/content/66556/abbott-hepatitis-c-combo-impressive-in-small-study.html
